

## Study: ENGOT-ov51 / NItCHE

Randomized Phase III Trial on Niraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment. (ENGOT Ov51-MITO 33: NItCHE trial).

### MaNGO Sites:

Prov.	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon	Yes
LC	Lecco	Ospedale Manzoni	Federica Villa	Yes
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	Yes
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	Yes

\* **MaNGO Principal Investigator**